6945-36-4 Usage
General Description
4-HYDROXYIMINO-PENTANOIC ACID, also known as pipecolic acid, is a naturally occurring compound found in various organisms including plants, animals, and humans. It is a non-protein amino acid that plays a crucial role in the metabolism of lysine and the synthesis of the neurotransmitter gamma-aminobutyric acid (GABA). Pipecolic acid has been linked to various biological processes, including immune response modulation, neuroprotection, and oxidative stress reduction. Its potential therapeutic applications include treatments for inflammatory and neurological disorders, as well as a possible role in preventing age-related cognitive decline. Additionally, pipecolic acid has been studied for its potential as a biomarker in the diagnosis and monitoring of certain health conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 6945-36-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,4 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 6945-36:
(6*6)+(5*9)+(4*4)+(3*5)+(2*3)+(1*6)=124
124 % 10 = 4
So 6945-36-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H9NO3/c1-4(6-9)2-3-5(7)8/h9H,2-3H2,1H3,(H,7,8)/b6-4-
6945-36-4Relevant articles and documents
Acyl acid derivative and preparation method and medical application thereof
-
Paragraph 0443-0446, (2020/07/02)
The invention relates to an acyl acid derivative as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and the invention also relates to a use thereof as an active ingredient in the prevention and/or treatment of muscle atrophy-related diseases, including myogenic muscle atrophy, disuse muscle atrophy, senile muscle atrophy, neurogenic muscle atrophy, and a use in the prevention and/or treatment of obesity, fatty liver, cardiovascular and cerebrovascular diseases, metabolic diseases, and anti-aging, wherein the definition of each group in the general formula (I) is the same as the definition in the specification.
